#ADA24: Gilead, Viking and Biohaven detail promising preclinical research in obesity and NASH

In a twist, preclinical research in metabolic disease is peaking more investor interest at the American Diabetes Association’s annual meeting than in past years.

As the GLP-1 and weight loss market becomes increasingly crowded, more companies have turned to earlier-stage candidates that use different mechanisms of action than GLP-1s. They’re also pivoting away from focusing on weight loss percentages and toward other markers of success, like preservation of lean mass, impact on the liver and cardiovascular benefits.

William Blair analyst Andy Hsieh told Endpoints News that investor interest in preclinical candidates is twofold: the commercial opportunity in the obesity space is “vast,” and potentially worth up to $150 billion, and companies are already working on the next generation of therapies, creating a “trickling down” effect.

“I think that’s what people are interested in in preclinical assets, which is: what’s next?” Hsieh said. “What’s beyond the GLP-1s?”

Gilead moves into obesity 


Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks